Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EPS Bio TechnologyROCO:4183 70 EV-to-EBITDA is 30.16 as of Sep. 04, 2026, which is 249% above its 10-year median of 8.63. GuruFocus rates ROCO:4183 with a GF Score™ of 70/100 and a GF Value™ of NT$18.35 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 515 Medical Devices & Instruments companies, EPS Bio Technology ranks worse than 77.48% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, EPS Bio Technology's enterprise value is NT$339.5 Mil.
EPS Bio Technology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$11.3 Mil. Therefore, EPS Bio Technology's EV-to-EBITDA for today is 30.16.
The historical rank and industry rank for EPS Bio Technology's EV-to-EBITDA or its related term are showing as below:
ROCO:4183'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -149.93 Med: 8.63 Max: 89.41
Current: 30.16
During the past 13 years, the highest EV-to-EBITDA of EPS Bio Technology was 89.41. The lowest was -149.93. And the median was 8.63.
ROCO:4183's EV-to-EBITDA is ranked worse than 77.48% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.26
vs ROCO:4183: 30.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EPS Bio Technology (ROCO:4183) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EPS Bio Technology's PE Ratio (TTM) for today is calculated as:
EPS Bio Technology's share price for today is NT$14.00.
EPS Bio Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for EPS Bio Technology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4183 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, EPS Bio Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EPS Bio Technology EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EPS Bio Technology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EPS Bio Technology's EV-to-EBITDA falls into.
EPS Bio Technology's current Enterprise Value is NT$339.5 Mil.
EPS Bio Technology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$11.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS Bio Technology (ROCO:4183) has a EV-to-EBITDA of 30.16 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EPS Bio Technology. This is 249% above median its historical median of 8.63. According to the industry distribution chart, EPS Bio Technology ranks #399 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 77.5%.
Is EPS Bio Technology's EV-to-EBITDA too high?
EPS Bio Technology's current EV-to-EBITDA of 30.16 is 249% above median its 10-year median of 8.63. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.26. EPS Bio Technology's value of 30.16 is 111.5% above this industry median. Based on the distribution chart, EPS Bio Technology ranks #399 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, EPS Bio Technology has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EPS Bio Technology's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EPS Bio Technology ranks #399 out of 515 companies for EV-to-EBITDA. This places EPS Bio Technology in the lower half of its industry. The industry median EV-to-EBITDA is 14.26. EPS Bio Technology's value of 30.16 is 111.5% above this benchmark. While the company's 10-year median is 8.63 vs. the industry median of 14.26, EPS Bio Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.26, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EPS Bio Technology's current EV-to-EBITDA of 30.16 is 111.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EPS Bio Technology. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EPS Bio Technology's current EV-to-EBITDA is 30.16, which is 249% above median its own 10-year median of 8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EPS Bio Technology stock overvalued right now?
Based on GuruFocus' analysis, EPS Bio Technology (ROCO:4183) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$18.35, compared to a current price of NT$14.00 — trading 23.7% below its estimated fair value. The current EV-to-EBITDA is 30.16, which is 249% above median its 10-year median of 8.63 and 111.5% above the Medical Devices & Instruments industry median of 14.26. EPS Bio Technology's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For EPS Bio Technology (ROCO:4183), the current EV-to-EBITDA is 30.16 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EPS Bio Technology (ROCO:4183) Overvalued in 2026?
Based on GuruFocus' analysis, EPS Bio Technology stock appears to be undervalued.
The current stock price of NT$14.00 is trading 23.7% below its estimated GF Value™ of NT$18.35.
GuruFocus considers EPS Bio Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4183:
EV-to-EBITDA: 30.16 (249% above median its 10-year median of 8.63)
GF Value™: NT$18.35 vs. price of NT$14.00 (23.7% below fair value)
Industry Position: 111.5% above the Medical Devices & Instruments median (#399 of 515)
No single metric tells the full story. See the ROCO:4183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EPS Bio Technology Corp operates in medical equipment manufacturing, international trade, intellectual property, and research, design, development, manufacture and sale of blood glucose measuring system and cirrhosis testing system. Its products include Test sheet and Glucose machine. Geographically it operates in Germany, Iran, Kingdom of Saudi Arabia, Switzerland, Las Vegas, and Others with majority of the revenue deriving from Germany.
70GF Score
Get the complete analysis for ROCO:4183
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4183 has been successfully added to your 
